TIGERMED Launches RMB500 Million–1 Billion A-Share Buyback for Incentives and Capital Reduction

Bulletin Express
05/19

Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) plans to repurchase between RMB500 million and RMB1 billion of its A-shares through centralized price bidding, according to a circular dated 19 May 2026.

Key terms • Price cap: RMB60.00 per share, no higher than 150% of the average trading price over the 30 trading days prior to the board approval on 13 May 2026. • Estimated volume: 8.33 million–16.67 million A-shares, equivalent to 0.97%–1.94% of total issued shares and 1.13%–2.26% of A-share capital. • Use of shares: up to 60% will serve future equity incentive or employee stock-ownership plans; at least 40% will be cancelled to reduce registered capital. • Funding source: the company’s own or self-raised funds; no proceeds from the previous H-share issuance will be used. • Timeline: buyback window extends up to 12 months after shareholder approval or ends earlier if the RMB1 billion ceiling is reached or the general meeting terminates the programme. • Trading blackout: no repurchases during opening/closing call auctions, trading days without price limits, or periods involving undisclosed material events.

Financial impact As of 31 March 2026 (unaudited), TIGERMED reported total assets of RMB28.80 billion, shareholders’ equity of RMB20.92 billion and current assets of RMB6.63 billion. A full RMB1 billion buyback would account for 3.47% of total assets, 4.78% of shareholders’ equity and 15.08% of current assets. Management states the exercise will not materially affect operations, liquidity or future development.

Shareholder meetings The second extraordinary general meeting and corresponding A- and H-share class meetings will be held on 9 June 2026 in Hangzhou to vote on the special resolution authorising the buyback and related mandates.

Record date The register of H-shareholders will be closed from 4 June to 9 June 2026 inclusive; transfers must be lodged by 16:30 on 3 June 2026 to qualify for voting rights.

If approved, the board will be authorised to adjust buyback parameters, open specific securities accounts, amend the articles of association for capital changes, and handle all ancillary matters until completion of the programme.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10